domest
cat
felin
caliciviru
fcv
common
import
pathogen
radford
et
al
typic
result
upper
respiratori
tract
sign
ulcer
oral
lesion
less
frequent
diseas
manifest
includ
lame
syndrom
pneumonia
felin
chronic
gingivostomat
syndrom
fcg
lyon
recent
recognit
fcvassoci
virul
system
diseas
fcvvsd
condit
associ
high
morbid
mortal
even
vaccin
adult
cat
hurley
syke
pedersen
et
al
inactiv
modifi
live
fcv
vaccin
avail
help
control
calicivirusrel
diseas
cat
gener
effect
reduc
sever
durat
clinic
sign
prevent
infect
shed
radford
et
al
high
level
antigen
variabl
amongst
fcv
isol
rais
concern
regard
level
cross
protect
afford
older
vaccin
radford
et
al
appar
limit
protect
afford
isol
associ
fcvvsd
hurley
syke
given
concern
signific
impact
viru
cat
safe
effect
antivir
therapeut
would
significantli
advanc
felin
medicin
felin
caliciviru
fcv
import
viral
pathogen
domest
cat
caus
clinic
sign
rang
mild
sever
oral
ulcer
upper
respiratori
tract
diseas
sever
fatal
system
diseas
current
therapeut
option
limit
direct
act
antivir
avail
treatment
studi
screen
panel
compound
potenti
antivir
activ
fcv
strain
recent
field
isol
vitro
use
resazurinbas
cytopath
effect
cpe
inhibit
assay
mefloquin
demonstr
mark
inhibitori
effect
fcv
induc
cpe
albeit
rel
low
select
index
orthogon
assay
confirm
inhibit
cpe
associ
signific
reduct
viral
replic
mefloquin
exhibit
strong
inhibitori
effect
panel
seven
recent
fcv
isol
australia
calcul
valu
field
isol
approxim
lower
refer
strain
fcv
vitro
combin
therapi
recombin
felin
interferonv
biolog
respons
modifi
current
regist
treatment
fcv
demonstr
addit
effect
concurr
reduct
mefloquin
result
first
report
antivir
effect
mefloquin
caliciviru
support
vitro
vivo
evalu
compound
antivir
therapeut
fcv
elsevi
bv
right
reserv
current
direct
act
antivir
drug
regist
treatment
fcv
although
immun
modul
drug
recombin
felin
interferonv
rfeifnv
like
indirect
antivir
properti
regist
indic
fcv
treatment
efficaci
human
felin
interferon
demonstr
vitro
fcv
fulton
burg
mochizuki
et
al
taira
et
al
truyen
et
al
use
rfeifnv
report
posit
therapeut
effect
fcv
infect
cat
experiment
field
efficaci
trial
ninomiya
et
al
ohe
et
al
treatment
rfeifnv
also
associ
improv
clinic
sign
cat
refractori
fcg
doubleblind
placebocontrol
studi
howev
fcv
shed
monitor
make
unclear
whether
improv
due
antivir
immunomodulatori
properti
interferon
hennet
et
al
recent
felin
caliciviru
specif
antivir
phosphorodiamid
morpholino
oligom
pmo
test
natur
occur
outbreak
fcvvsd
smith
et
al
highli
efficaci
treatment
result
improv
surviv
reduct
shed
rapid
clinic
recoveri
current
studi
screen
panel
compound
antivir
activ
fcv
use
resazurinbas
cpe
inhibit
assay
antivir
effect
compound
identifi
screen
confirm
plaqu
reduct
viru
yield
reduct
assay
effect
compound
test
panel
recent
fcv
field
isol
australia
confirm
effect
clinic
relev
virus
effect
compound
also
test
combin
rfeifnv
current
licenc
treatment
fcv
australia
crandel
ree
felin
kidney
crfk
cell
line
propag
outlin
previous
mcdonagh
et
al
refer
felin
caliciviru
strain
kindli
provid
professor
gilkerson
univers
melbourn
field
isol
fcv
collect
cat
sydney
melbourn
grown
crfk
cell
confirm
fcv
caus
agent
cpe
clinic
sampl
indirect
immunofluoresc
assay
perform
use
antifcv
monoclon
antibodi
clone
custom
monoclon
intern
sacramento
usa
virus
titrat
carboxymethylcellulos
plaqu
assay
crfk
cell
store
singl
use
aliquot
nineteen
compound
select
base
report
vitro
antivir
effect
rna
virus
mcdonagh
et
al
determin
appropri
screen
concentr
cytotox
compound
investig
use
sequenti
resazurin
sulforhodamin
b
assay
previous
report
mcdonagh
et
al
test
compound
concentr
select
subsequ
antivir
screen
result
cell
viabil
greater
shown
tabl
stock
solut
prepar
outlin
previous
mcdonagh
et
al
maximum
final
inwel
dmso
concentr
use
studi
demonstr
signific
effect
cell
viabil
viral
replic
data
shown
antivir
screen
perform
use
modif
optimis
resazurinbas
cpe
inhibit
assay
outlin
previous
mcdonagh
et
al
h
compound
exposur
cell
infect
fcv
strain
moi
ml
well
infect
period
h
ml
dilut
stock
resazurin
dmem
final
well
concentr
resazurin
nm
ad
final
h
durat
compound
exposur
assay
h
prior
infect
assay
endpoint
therebi
allow
identif
agent
act
stage
viral
lifecycl
plate
remov
incub
final
min
allow
plate
media
equilibr
room
temperatur
fluoresc
signal
measur
fluostar
omega
micropl
reader
bmg
labtech
mornington
vic
australia
use
nm
excit
filter
nm
emiss
filter
flash
per
well
bottom
read
mode
treatment
perform
triplic
result
repres
mean
ae
se
three
independ
experi
percentag
inhibit
cpe
calcul
rfu
tx
mean
fluoresc
intens
treat
infect
cell
rfu
v
mean
fluoresc
intens
untreat
infect
cell
rfu
v
mean
fluoresc
intens
untreat
uninfect
cell
compound
show
mark
moder
mild
antivir
effect
defin
show
inhibit
cpe
respect
compound
demonstr
mark
cpe
inhibit
classifi
candid
compound
select
characteris
use
optimis
fcv
cpe
inhibit
assay
concentrationrespons
experi
conduct
serial
dilut
effect
compound
identifi
screen
enabl
calcul
select
index
repeat
cytotox
screen
perform
concurr
cytotox
screen
perform
per
cpe
inhibit
assay
except
cell
mock
infect
dmem
treatment
perform
triplic
repeat
three
independ
experi
result
present
mean
ae
se
data
analysi
conduct
graphpad
prism
window
graphpad
softwar
san
diego
ca
usa
inhibitori
concentr
cytotox
concentr
valu
calcul
use
inbuilt
nonlinear
curv
fit
function
follow
log
transform
compound
concentr
select
index
si
compound
calcul
accord
follow
formula
plaqu
reduct
viru
yield
reduct
assay
perform
confirm
antivir
effect
candid
compound
identifi
use
modif
method
previous
describ
mcdonagh
et
al
viru
yield
reduct
assay
five
concentr
test
compound
assess
cell
expos
compound
h
prior
infect
fcv
moi
ml
dmem
h
post
infect
hpi
cellular
morpholog
assess
cpe
use
invert
phase
contrast
microscop
olympu
supernat
harvest
store
prior
titrat
extracellular
viru
use
assay
rel
viral
titr
calcul
treatment
valu
untreat
control
defin
treatment
time
point
perform
triplic
repeat
two
independ
experi
result
repres
mean
ae
se
plaqu
reduct
assay
perform
use
modif
plaqu
assay
previous
describ
mcdonagh
et
al
approxim
pfu
fcv
ad
per
well
rel
plaqu
number
calcul
treatment
valu
untreat
control
defin
treatment
perform
duplic
result
repres
mean
ae
se
three
independ
experi
use
resazurinbasedcp
inhibit
assay
antivir
efficaci
identifi
candid
compound
seven
current
circul
field
isol
investig
detail
field
isol
shown
tabl
assay
condit
ident
use
screen
except
cell
infect
differ
field
isol
untreat
cell
also
infect
differ
isol
viru
control
uninfect
untreat
cell
includ
posit
control
treatment
perform
triplic
well
viru
repeat
three
independ
experi
data
express
mean
ae
se
investig
antivir
efficaci
differ
isol
resazurinbas
cpe
inhibit
concentrationrespons
studi
conduct
use
field
isol
treatment
perform
triplic
result
repres
mean
ae
se
three
independ
experi
calcul
si
valu
perform
previous
describ
use
optimis
resazurinbas
cpe
inhibit
assay
cell
pretreat
vari
combin
rfeifnv
mefloquin
concentr
unit
ml
mm
respect
prior
infect
fcv
moi
treatment
perform
triplic
repeat
three
independ
experi
data
present
mean
ae
se
valu
calcul
previous
describ
mefloquin
concentr
mm
compound
test
demonstr
mark
inhibit
viru
induc
cpe
fig
compound
demonstr
limit
inhibitori
effect
cpe
includ
among
four
compoundsribavirin
lactoferrin
chloroquin
rfeifnv
previous
demonstr
vitro
efficaci
fcv
kreutz
seal
mccann
et
al
povey
truyen
et
al
titrat
mefloquin
demonstr
clear
concentrationrespons
relationship
almost
complet
inhibit
cpe
highest
test
concentr
reduc
zero
inhibit
lowest
test
concentr
calcul
si
valu
shown
fig
orthogon
test
confirm
cpe
inhibit
associ
mark
reduct
product
progeni
virion
use
viru
yield
reduct
assay
mefloquin
demonstr
concentr
depend
inhibit
viral
replic
assay
hpi
fig
high
concentr
reduct
viral
titr
hpi
greater
log
hpi
reduc
log
calcul
si
valu
hpi
shown
fig
plaqu
reduct
assay
confirm
find
resazurinbas
cpe
inhibit
assay
pretreat
mefloquin
result
concentrationdepend
reduct
plaqu
number
calcul
mm
confid
interv
result
select
index
plaqu
size
morpholog
vari
consider
treat
untreat
cell
howev
gener
plaqu
size
smaller
plaqu
morpholog
consist
well
treat
higher
concentr
mefloquin
mefloquin
demonstr
similar
inhibit
viru
induc
cpe
test
field
isol
refer
strain
fcv
fig
assess
quantit
differ
efficaci
mefloquin
differ
field
isol
concentrationrespons
experi
conduct
use
field
isol
mefloquin
demonstr
concentrationdepend
inhibit
isol
similar
shape
concentrationrespons
curv
valu
less
half
fcv
fig
rfeifnv
exert
concentrationdepend
addit
antivir
effect
vitro
combin
mefloquin
fig
increas
rfeifnv
concentr
unit
ml
result
shift
concentrationrespons
curv
left
correspond
decreas
calcul
valu
assay
addit
effect
rfeifnv
antivir
efficaci
mefloquin
fig
result
fcv
antivir
screen
experi
cell
pretreat
variou
compound
h
prior
infect
fcv
moi
antivir
efficaci
determin
hpi
use
resazurinbas
cpe
inhibit
assay
b
concurr
cytotox
screen
perform
use
protocol
except
cell
mock
infect
treatment
perform
triplic
repeat
three
independ
experi
result
repres
mean
ae
se
ata
aurintricarboxyl
acid
hma
hexamethylen
amilorid
red
dot
line
inhibit
cpe
appear
peak
unit
ml
greater
concentr
result
reduct
valu
demonstr
mark
inhibitori
effect
mefloquin
replic
associ
cytopath
effect
fcv
cell
cultur
initi
screen
confirmatori
assay
perform
cultur
adapt
vaccin
strain
howev
subsequ
test
seven
current
australian
field
isol
demonstr
antivir
efficaci
remain
excel
potenti
relev
virus
concentrationrespons
studi
confirm
mefloquin
potent
inhibitor
field
isol
refer
strain
combin
treatment
rfeifnv
result
addit
effect
reduct
valu
mefloquin
data
provid
import
preliminari
inform
potenti
use
mefloquin
deriv
antivir
therapeut
treatment
fcvassoci
diseas
initi
screen
orthogon
confirmatori
assay
perform
fcv
wellcharacteris
strain
origin
isol
glenn
et
al
fcv
chosen
screen
due
well
characteris
vitro
growth
properti
howev
unclear
whether
fcv
use
current
studi
repres
current
circul
virus
due
natur
viral
evolut
circul
field
virus
last
half
centuri
face
vaccin
base
vaccin
cell
cultur
adapt
occur
high
passag
number
therefor
possibl
result
obtain
fcv
may
repres
efficaci
circul
strain
particularli
given
known
genet
heterogen
fcv
coyn
et
al
addit
antivir
screen
perform
panel
seven
recent
fcv
isol
australia
variat
suscept
antivir
agent
aris
rapidli
due
viral
evolut
respons
select
pressur
impos
use
antivir
drug
popul
howev
may
also
preexist
treatment
naiv
popul
ferrari
et
al
show
signific
variabl
sensit
influenza
virus
neuraminidas
inhibitor
zanamivir
oseltamivir
even
virus
isol
prior
widespread
use
drug
contrast
current
studi
test
fcv
isol
suscept
inhibitori
effect
mefloquin
base
cpe
inhibit
assay
concentrationrespons
studi
demonstr
greater
twofold
increas
potenc
two
field
isol
test
compar
refer
viru
fcv
although
studi
requir
determin
whether
gener
featur
field
isol
whether
uniqu
two
test
isol
highlight
consider
must
given
viral
strain
use
screen
combin
antivir
therapi
common
practic
signific
human
viral
infect
hiv
hcv
feld
hoofnagl
shafer
vuitton
offer
sever
potenti
theoret
benefit
monotherapi
includ
rapid
complet
inhibit
replic
reduct
likelihood
viral
escap
potenti
reduc
dose
individu
drug
therebi
minimis
dosedepend
advers
effect
hcv
combin
therapi
ribavirin
interferon
histor
standard
care
demonstr
good
clinic
success
feld
hoofnagl
rfeifnv
approv
therapeut
cat
sought
investig
use
combin
mefloquin
interferon
monotherapi
previous
demonstr
small
antivir
effect
fcv
vitro
mochizuki
et
al
truyen
et
al
vivo
efficaci
also
report
experiment
field
studi
fcv
ninomiya
et
al
uchino
et
al
cite
ohe
et
al
concentr
use
current
studi
howev
monotherapi
rfeifnv
provid
limit
protect
cpe
may
reflect
differ
sensit
viru
yield
reduct
assay
compar
cpe
inhibit
assay
mcdonagh
et
al
well
differ
experiment
infect
condit
combin
therapi
rfeifnv
mefloquin
howev
demonstr
addit
effect
increas
concentr
interferon
result
reduct
mefloquin
combin
may
prove
use
therapeut
option
fcv
infect
particularli
reduc
dose
mefloquin
possibl
concomit
reduct
risk
advers
reaction
result
studi
expand
known
antivir
spectrum
mefloquin
vitro
efficaci
previous
report
hiv
jc
viru
felin
coronaviru
brickelmai
et
al
mcdonagh
et
al
owen
et
al
mechan
action
mefloquin
divers
group
virus
known
clear
whether
antivir
efficaci
due
common
broad
spectrum
mechan
action
investig
like
mechan
action
mefloquin
fcv
conduct
current
studi
given
document
effect
mefloquin
endocytosi
morpholog
chang
suggest
alter
pathway
crfk
cell
mcdonagh
et
al
tempt
specul
antivir
effect
fcv
may
aris
perturb
pathway
cellular
entri
fcv
occur
via
receptor
mediat
endocytosi
follow
bind
cellular
receptor
fjama
stuart
brown
treatment
known
inhibitor
differ
step
viral
entri
includ
inhibitor
endocytosi
reveal
fcv
entri
involv
clathrin
coat
pit
endosom
acidif
requir
infect
agreement
previou
report
kreutz
seal
show
chloroquin
inhibit
viral
replic
assay
condit
current
studi
chloroquin
provid
protect
viru
induc
cpe
suggest
viral
inhibit
aris
lysosomotrop
effect
mefloquin
glaumann
et
al
effect
consider
potent
mefloquin
chloroquin
altern
mechan
unrel
accumul
lysosom
action
adenosin
analogu
hypothesis
jc
viru
brickelmai
et
al
may
account
observ
antivir
effect
although
mefloquin
human
approv
pharmaceut
signific
bodi
literatur
regard
pharmacokinet
safeti
use
cat
report
well
recognis
due
defici
number
drug
metabol
pathway
pharmacokinet
certain
drug
cat
quit
differ
speci
fact
consid
extrapol
human
pharmacokinet
data
speci
court
valu
calcul
field
isol
base
inhibit
cpe
approxim
mm
lower
plasma
concentr
mefloquin
report
human
studi
mm
depend
dose
regimen
kollaritsch
et
al
simpson
et
al
extrapol
avail
data
therefor
may
possibl
achiev
vivo
concentr
mefloquin
within
therapeut
rang
howev
potenti
cytotox
must
consid
given
low
si
compound
crfk
cell
studi
identifi
mefloquin
potent
inhibitor
fcv
vitro
present
low
micromolar
concentr
first
report
antivir
activ
mefloquin
caliciviru
test
panel
recent
australian
fcv
isol
demonstr
antivir
effect
mefloquin
refer
strain
fcv
extend
clinic
relev
isol
evid
antagon
use
concurr
rfeifnv
investig
optimis
compound
clinic
use
treat
seriou
manifest
fcv
infect
warrant
consider
given
investig
effect
mefloquin
member
calicivirida
medic
veterinari
import
